The Pharmacology Core will provide analytical, drug metabolism and parmacokinetic services with the aim of relating drug (or appropriate metabolite) concentrations to treatment outcome. We specifically propose to support seven projects in the renewal period. As examples, we will assist in the search for a relationship between actual exposure to active metabolites of cyclophosphamide and organ toxicity (Project 5); support a comparison of marrow versus peripheral blood stem cell transplantation in patients whose busulfan levels will not be allowed to fall below 900 ng/mL, with relapse as the primary end point and the definition of a relationship between elevated busulfan levels and organ toxicity as the secondary endpoint (Projects 1 and 6); assist in the determination of a relationship between ganciclovir exposure and neutropenia in the early post-engraftment period (Project 7); and provide pharmacokinetic support to Phase I/II and Phase III trials of mofetil mycophenolate (Project 3). In some instances (e.g., Project 5); we propose to identify the causes of interpatient variability in actual exposure to active compounds at a given dose of drug in order to develop intervention strategies to minimize untoward effects and maximize desired outcome. The Pharmacology Core also will be available to address special clinical pharmacology needs that may arise in Program components in order to implement new initiatives. By establishing a central facility for planning and coordination of sampling protocols and the analytical processing of the many blood and other and other samples involved, the analytical and pharmacokinetic precision and information needed to accomplish the proposed research will be assured.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA018029-22A1
Application #
6236405
Study Section
Project Start
1997-08-28
Project End
1997-11-30
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
22
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Armenian, Saro H; Yang, Dongyun; Teh, Jennifer Berano et al. (2018) Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Adv 2:1756-1764
Petersdorf, Effie W; Stevenson, Philip; Malkki, Mari et al. (2018) Patient HLA Germline Variation and Transplant Survivorship. J Clin Oncol 36:2524-2531
Yeung, Cecilia C S; McElhone, Scott; Chen, Xue Yan et al. (2018) Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome. Mod Pathol 31:569-580
Lee, Stephanie J; Onstad, Lynn; Chow, Eric J et al. (2018) Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica 103:1535-1541
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515

Showing the most recent 10 out of 1845 publications